6617 Share Price Performance
NT$0
-114.00 (-100.00%)
Price NT$0
Share Pricen/a
Gongwin Biopharm Holdings Co., Ltd. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
6617 Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
Gongwin Biopharm Holdings Co., Ltd. Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
- -1.16
- 70.78%
- -370.96%
- 5.3%
About 6617
- Founded
- 2014
- Employees
- n/a
- CEO
- WebsiteView website
Gongwin Biopharm Holdings Co., Ltd., a clinical-stage biopharmaceutical company, develops anticancer drugs in Hong Kong, China, and Singapore. It is developing PTS302, which has completed Phase III clinical trials for the treatment of lung cancer; PTS100, which is in Phase II clinical trials for the treatment of hepatocellular carcinoma; PTS02, which is in Phase I clinical trials for the treatment of adenoid cystic carcinoma; and PTS500 for the treatment of malignant pleural effusion. The company also develops animal medicines; engaged in the pet medical business; and wholesale and retail of the medical equipment. Gongwin Biopharm Holdings Co., Ltd. was founded in 2014 and is based in Taipei, Taiwan.
